DexCom Management

Management criteria checks 4/4

DexCom's CEO is Kevin Sayer, appointed in Jun 2011, has a tenure of 13.42 years. total yearly compensation is $15.71M, comprised of 7% salary and 93% bonuses, including company stock and options. directly owns 0.045% of the company’s shares, worth $13.05M. The average tenure of the management team and the board of directors is 3.7 years and 8.8 years respectively.

Key information

Kevin Sayer

Chief executive officer

US$15.7m

Total compensation

CEO salary percentage7.0%
CEO tenure13.4yrs
CEO ownership0.04%
Management average tenure3.7yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?

Nov 08
Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?

DexCom Growing Into Its Valuation, But Still No Bargain

Oct 25

DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings

Oct 21
DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings

DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships

Oct 16

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Sep 30
These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom: Investors Discounting Long CGM Growth Runway

Sep 19

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

Sep 16
We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

DexCom Q2 Earnings: Traditional Market Overreaction

Aug 07

Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

Jul 26
Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures

Jul 26

Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

Jul 12
Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

Jul 03

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Jun 28
DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Jun 03
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Dexcom: Positive Catalysts Ahead To Support Growth

May 13

If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

May 07
If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

DexCom: Attractive Discount After Strong Earnings Results

May 06

Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Apr 25
Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

Apr 12
Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Apr 11

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Mar 29
Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Mar 04
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom: A Wealth Compounder In Healthcare

Feb 14

DexCom: Stelo Stellar Outlook

Jan 17

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

Jan 15
DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

Jan 01
DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dec 18
DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Dec 05
A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

Nov 21
At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

Sep 28
DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

Sep 13
DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Aug 29
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Aug 14
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

Jun 05
DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

May 16
There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

Mar 21
Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Mar 03
These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Feb 13
DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

CEO Compensation Analysis

How has Kevin Sayer's remuneration changed compared to DexCom's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$681m

Jun 30 2024n/an/a

US$667m

Mar 31 2024n/an/a

US$639m

Dec 31 2023US$16mUS$1m

US$542m

Sep 30 2023n/an/a

US$377m

Jun 30 2023n/an/a

US$358m

Mar 31 2023n/an/a

US$293m

Dec 31 2022US$15mUS$953k

US$341m

Sep 30 2022n/an/a

US$244m

Jun 30 2022n/an/a

US$230m

Mar 31 2022n/an/a

US$258m

Dec 31 2021US$12mUS$900k

US$217m

Sep 30 2021n/an/a

US$577m

Jun 30 2021n/an/a

US$562m

Mar 31 2021n/an/a

US$530m

Dec 31 2020US$14mUS$800k

US$550m

Sep 30 2020n/an/a

US$231m

Jun 30 2020n/an/a

US$205m

Mar 31 2020n/an/a

US$148m

Dec 31 2019US$10mUS$691k

US$101m

Sep 30 2019n/an/a

-US$171m

Jun 30 2019n/an/a

-US$170m

Mar 31 2019n/an/a

-US$130m

Dec 31 2018US$10mUS$601k

-US$127m

Sep 30 2018n/an/a

US$43m

Jun 30 2018n/an/a

-US$5m

Mar 31 2018n/an/a

-US$33m

Dec 31 2017US$8mUS$546k

-US$50m

Compensation vs Market: Kevin's total compensation ($USD15.71M) is about average for companies of similar size in the US market ($USD12.73M).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.


CEO

Kevin Sayer (66 yo)

13.4yrs

Tenure

US$15,712,244

Compensation

Mr. Kevin Ronald Sayer has been Executive Chairman of DexCom, Inc. since July 30, 2018. Mr. Sayer has been the Chief Executive Officer of DexCom, Inc. since January 5, 2015 and as its President since June...


Leadership Team

NamePositionTenureCompensationOwnership
Kevin Sayer
Executive Chairman13.4yrsUS$15.71m0.045%
$ 13.0m
Jereme Sylvain
Executive VP4.7yrsUS$4.25m0.0090%
$ 2.6m
Jacob Leach
Executive VP & COO2.3yrsUS$4.94m0.066%
$ 19.4m
Michael Brown
Executive VP & Chief Legal Officer2.8yrsUS$4.34m0.0014%
$ 400.7k
Teri Lawver
Executive VP & Chief Commercial Officer1.8yrsUS$6.53m0.0017%
$ 491.4k
Girish Naganathan
Executive VP & CTO2.1yrsUS$4.05m0.0014%
$ 400.7k
Sean Christensen
Director of Corporate Affairs & Head of Investor Relationsno datano datano data
Matthew Dolan
Executive Vice President of Strategy3.7yrsno datano data
Leverne Marsh
Executive Vice President of Marketingless than a yearno datano data
Sadie Stern
Executive VP & Chief Human Resources Officer4.2yrsno data0.0059%
$ 1.7m
Donald Abbey
Executive Vice President of Global Business Services7.8yrsUS$2.92m0.043%
$ 12.6m
Barry Regan
Executive Vice President of Global Operations4yrsno data0.0020%
$ 582.0k

3.7yrs

Average Tenure

50yo

Average Age

Experienced Management: DXCM's management team is considered experienced (3.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kevin Sayer
Executive Chairman17yrsUS$15.71m0.045%
$ 13.0m
Mark Foletta
Lead Independent Director10yrsUS$393.51k0.014%
$ 4.2m
Steven Altman
Independent Director11yrsUS$343.40k0.014%
$ 4.2m
Eric Topol
Independent Director15.3yrsUS$346.49k0.097%
$ 28.3m
Nicholas Augustinos
Independent Director15yrsUS$362.21k0.0095%
$ 2.8m
Bridgette Heller
Independent Director5.2yrsUS$346.49k0.0056%
$ 1.6m
Kyle Malady
Independent Director4.1yrsUS$343.40k0.0040%
$ 1.2m
Karen Dahut
Independent Director4.3yrsUS$345.90k0.0039%
$ 1.1m
Richard Collins
Independent Director7.7yrsUS$345.90k0.010%
$ 2.9m
Rimma Driscoll
Independent Director1.3yrsUS$404.72k0%
$ 0

8.8yrs

Average Tenure

63yo

Average Age

Experienced Board: DXCM's board of directors are considered experienced (8.8 years average tenure).